Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Publication year range
1.
J Toxicol Sci ; 30(3): 165-74, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16141651

ABSTRACT

Indole-3-acetic acid (IAA), a natural auxin, induces microencephaly in rats exposed to IAA during gestation days (Days) 12-14, corresponding to the early stage of cerebral cortex development. The purpose of this study was to examine the effects of 5 IAA derivatives administration in pregnant rats on neuroepithelial cells in the embryos. N-Methylindole-3-acetic acid (1Me-IAA), 2-Methylindole-3-acetic acid (2Me-IAA), 2-Methyl-5-methoxyindole-3-acetic acid (2Me-5MeO-IAA), 5-Methoxyindole-3-acetic acid (5MeO-IAA), Indole butyric acid (IBA), and IAA were administered at 1,000 mg/kg except for 2Me-IAA at 500 mg/kg on Days 12, 13 and 14, and then embryos/fetuses were harvested on Day 14.5 or 21. The dams in the 1Me-IAA and 2Me-IAA groups exhibited rigidity and a decrease in locomotor activity. Although a decrease in the absolute brain weight was observed in the 1Me-IAA, 5MeO-IAA, IBA and IAA groups, a decrease in the relative brain weight was observed in only the IAA group. Histopathologically, apoptotic cells were observed mainly in the medial and dorsal layer of the neuroepithelium in the 5MeO-IAA and IAA groups on Day 14.5. The degree of induced neuroepithelial cell apoptosis was less in the 5MeO-IAA group than in the IAA group. However, it was confirmed that the histopathological changes induced by 5MeO-IAA were quite similar to the lesions induced by IAA and may have resulted from the same mechanisms.


Subject(s)
Brain/drug effects , Indoleacetic Acids/toxicity , Neuroepithelial Cells/drug effects , Administration, Oral , Animals , Apoptosis/drug effects , Brain/embryology , Brain/pathology , Female , Gestational Age , Hydroxyindoleacetic Acid/administration & dosage , Hydroxyindoleacetic Acid/analogs & derivatives , Hydroxyindoleacetic Acid/toxicity , Indoleacetic Acids/administration & dosage , Indoleacetic Acids/chemistry , Molecular Structure , Motor Activity/drug effects , Neuroepithelial Cells/pathology , Neurons/drug effects , Neurons/pathology , Organ Size/drug effects , Pregnancy , Rats , Rats, Wistar , Weight Gain/drug effects
2.
Neuro Endocrinol Lett ; 24(3-4): 259-62, 2003.
Article in English | MEDLINE | ID: mdl-14523367

ABSTRACT

OBJECTIVES: It is known since many years that the pineal gland plays an anticancer role, and melatonin (MLT), the most investigated pineal hormone, has been proven to exert antitumor activity. However, MLT would not be the only hormone responsible for the antitumor action of the pineal gland. In fact, recent advances in the pineal investigations have shown that pineal indoles other than MLT may also exert anticancer activity, namely the three main indoles, consisting of 5-methoxytriptamine (5-MTT), 5-methoxytryptophol (5-MTP) and 5-methoxy-indole acetic acid (5-MIA). Cancer progression has appeared to be associated with a concomitant decline in the pineal endocrine function. Therefore, the replacement of a complete pineal function in the advanced cancer patients would require the exogenous administration of the overall four pineal indoles. Several clinical studies have shown that MLT alone at pharmacological doses may induce a control of the neoplastic progression in about 30% of untreatable metastatic solid tumor patients. The present study was performed in an attempt to evaluate the therapeutic of a total pineal endocrine substitution therapy with its four indole hormones in cancer patients, for whom no other conventional therapy was available. METHODS: The study included 14 metastatic solid tumor patients, who had failed to respond to the conventional anticancer therapies. The pineal indoles were given orally according to a schedule elaborated in an attempt to reproduce their physiological circadian secretion during the daily photoperiod. MLT was given at 20 mg/day during the night, whereas the other indoles were given at 1 mg/day, by administering 5-MIA in the morning, 5-MTP at noon and 5-MTT in the afternoon. RESULTS: A disease-control was achieved in 9/14 (64%) patients, consisting of partial response (PR) in one patient and stable disease (SD) in the other 8 patients. The median time of disease-control (PR + SD) was 6 months (range: 4-10). CONCLUSIONS: This preliminary study shows that a total pineal endocrine replacement therapy by an exogenous administration of the overall four pineal indoles may induce a disease-control in about 60% of untreatable metastatic solid tumor patients. Then, these results would be clearly superior with respect to those described with MLT alone, by confirming in humans that MLT is not the only hormone responsible for the anticancer property of the pineal gland. Since Cartesius was the first author who suggested the fundamental role of the pineal in the connection between consciousness and biological life, this therapy could be defined as a Cartesian therapy.


Subject(s)
Antineoplastic Agents/therapeutic use , Hydroxyindoleacetic Acid/analogs & derivatives , Indoles/therapeutic use , Neoplasm Metastasis/drug therapy , Pineal Gland/physiology , 5-Methoxytryptamine/administration & dosage , 5-Methoxytryptamine/therapeutic use , Aged , Aged, 80 and over , Antioxidants/administration & dosage , Antioxidants/therapeutic use , Disease Progression , Female , Humans , Hydroxyindoleacetic Acid/administration & dosage , Hydroxyindoleacetic Acid/therapeutic use , Indoles/administration & dosage , Male , Melatonin/administration & dosage , Melatonin/therapeutic use , Middle Aged , Neoplasm Metastasis/pathology , Palliative Care , Pineal Gland/metabolism
3.
Anal Biochem ; 196(1): 170-3, 1991 Jul.
Article in English | MEDLINE | ID: mdl-1716073

ABSTRACT

A method for the routine quantitative determination of the major serotonin metabolite 5-hydroxyindole-3-acetic acid (5-HIAA) in urine is described. 5-HIAA was analyzed without prior sample cleanup, using an automated high-performance liquid chromatography system with isocratic elution and electrochemical detection (+0.60 V versus a Ag/AgCl reference electrode). The urine samples were mixed with a solution of the internal standard (5-hydroxyindole-3-propionic acid) and centrifuged. The supernatant was transferred to sealed glass vials, and a 2-microliters aliquot was injected directly onto a C18 reversed-phase analytical column, using an automatic sample injector. Samples of urine could be stored for several months at -80 or at +7 degrees C for 2 days without loss of 5-HIAA. However, a gradual decline with time occurred in crude samples stored at room temperature or above, as well as in urine samples diluted with the mobile phase. The detector response was linear in the range of 0-65 mumol/l 5-HIAA, and the intra- and interassay coefficients of variation were about 5 and 7%, respectively (n = 10).


Subject(s)
Chromatography, High Pressure Liquid/methods , Hydroxyindoleacetic Acid/urine , Electrochemistry , Humans , Hydroxyindoleacetic Acid/administration & dosage , Kinetics , Reproducibility of Results , Sensitivity and Specificity
5.
Science ; 173(3998): 738-40, 1971 Aug 20.
Article in English | MEDLINE | ID: mdl-5109594

ABSTRACT

5-Hydroxyindoleacetic acid applied intracisternally in cats does not appear in spinal fluid. Changes of 5-hydroxyindoleacetic acid concentration in the spinal cord are clearly reflected in the perfusate of the spinal subarachnoid space. Thus, 5-hydroxyindoleacetic acid in the spinal fluid originates from the spinal cord and reflects metabolic changes of 5-hydroxytryptamine in the spinal tissue, but not those in the brain.


Subject(s)
Hydroxyindoleacetic Acid/cerebrospinal fluid , Animals , Brain/metabolism , Cats , Hydroxyindoleacetic Acid/administration & dosage , Hydroxyindoleacetic Acid/analysis , Hydroxyindoleacetic Acid/biosynthesis , Hydroxyindoleacetic Acid/blood , Injections, Spinal , Perfusion , Serotonin/analysis , Serotonin/metabolism , Spinal Cord/analysis , Spinal Cord/metabolism , Subarachnoid Space , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...